BioCryst Pharmaceuticals (BCRX): The stock had negative money flow to the tune of ($16.58 million) on Monday, which shows that the traders are selling the stock on the price strength. The inflow of money on upticks was $3.39 million, whereas, the outflow of money on downticks was $19.97 million and the ratio between the two was 0.17. The block trade had a negative net money flow of ($16.29 million). The total block trade value undertaken on upticks was $0.47 million. On the other hand, downticks amounted to $16.76 million of the traded value, which shows distribution in the stock by traders. The ratio between uptick and downtick was 0.03. BioCryst Pharmaceuticals (BCRX) closed with marginal gains of 1 cents to end the day at $5.04, an increase of 0.2% over the previous days close. The stock recorded 21.74% for the week.
Shares of BioCryst Pharmaceuticals, Inc. rose by 12.65% in the last five trading days and 59.46% for the last 4 weeks. BioCryst Pharmaceuticals, Inc. is up 54.25% in the last 3-month period. Year-to-Date the stock performance stands at -54.26%.
BioCryst Pharmaceuticals (NASDAQ:BCRX): The stock opened at $5.11 on Monday but the bulls could not build on the opening and the stock topped out at $5.19 for the day. The stock traded down to $4.68 during the day, due to lack of any buying support eventually closed down at $4.72 with a loss of -6.35% for the day. The stock had closed at $5.04 on the previous day. The total traded volume was 2,130,819 shares.
In a related news,The officer (Senior Vice President and CFO) of Biocryst Pharmaceuticals Inc, Staab Thomas R Ii sold 14,577 shares at $4.43 on August 9, 2016. The Insider selling transaction had a total value worth of $64,576. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB, BCX4161, BCX7353 and other second generation HAE compounds, BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza, in the United States as RAPIVAB, in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.